- Global Pharma News & Resources

Centronuclear Myopathies Drug Market Study 2026: Poised For A Strong Growth By Eminent Players – Audentes Therapeutics, Ionis Pharmaceuticals, Inc, Dynacure

Data Bridge Market Research Added new upcoming report title “Centronuclear Myopathies Drug Market Study 2026: Poised For A Strong Growth By Eminent Players – Audentes Therapeutics, Ionis Pharmaceuticals, Inc, Dynacure” to its database.

Global centronuclear myopathies drug market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth.

Few of the major competitors currently working in the global centronuclear myopathies drug market are Audentes Therapeutics, Ionis Pharmaceuticals, Inc, Dynacure, Valerion Therapeutics, Biophytis, ARMGO Pharma Inc, Stealth BioTherapeutics Inc and others.

Request Sample of Global Centronuclear Myopathies Drug Market Status and Future Forecast 2019-2026 @

Market Definition:

Centronuclear Myopathy is a rare genetic disease which primarily causes muscle weakness. The protein myotubularin which is essential for our ability to breathe and swallow is either missing or dysfunctional due to a mutation to the MTM1 gene. This protein is essential for our muscles to contract. Many patients with centronuclear myopathy need immediate intervention and need around-the-clock care including ventilator support in a feeding tube.

According to the statistics published in the Valerion Therapeutics, it was estimated the overall prevalence of this disease is 1: 50,000 male births. Huge financial support from the government and increase in strategic alliances between the companies are key factors for market growth.

Market Drivers

Family history of centronuclear myopathy is driving the market growthIncrease special designation from the regulatory authorities is boosting the market growthHigh specific demand of novel treatment is accelerating the market growthHuge financial support to the researchers for developing novel intervention is enhancing the market growth

Market Restraints

Limited availability of medicinal treatment options due to low prevalence of centronuclear myopathy is restraining the market growthFewer approvals of drugs from the regulatory authorities is hindering the market growthLack of trained personnel and stringent safety regulations is hampering the market growth


By Types

Myotubular MyopathyAutosomal Centronuclear MyopathiesOthers

By Treatment Type

Night Time VentilationGastrostomyPhysiotherapyAntibioticsOthers

By Diagnosis

Muscle BiopsyMolecular TestingOthers

By End Users

HospitalsHomecareSpecialty ClinicsOthers

By Distribution Channel

Hospital PharmacyOnline PharmacyRetailersOthers

By Geography

North AmericaS.CanadaMexicoSouth AmericaBrazilRest of South AmericaEuropeGermanyFranceUnited KingdomItalySpainRussiaTurkeyBelgiumNetherlandsSwitzerlandRest of EuropeAsia-PacificJapanChinaSouth KoreaIndiaAustraliaSingaporeThailandMalaysiaIndonesiaPhilippinesRest of Asia PacificMiddle East & AfricaSouth AfricaRest of Middle East & Africa

View Detailed Table of Contents @

Key Developments in the Market:

In August 2019, Dynacure in a collaboation with Ionis Pharmaceuticals, Inc received Orphan Drug designation from the FDA for the treatment of Centronuclear Myopathies. With the Orphan Drug designation, companies can obtain financial incentives from the government along with 7 year period marketing exclusivity.

In November 2017, Ionis Pharmaceuticals, Inc. out-licensed worldwide development and commercialization right to Dyanacure for IONIS-DNM2-2.5Rx (Dyn101), a generation 2.5 antisense drug targeting dynamin 2 receptor for the treatment of centronuclear myopathy (CNM). Under the deal terms, Dyanacure paid USD 5.00 million as a licensee fee and eligible to pay additional cash of nearly USD 205.00 million as milestone payment. Additionally, Ionis Pharmaceuticals, Inc. is entitled to receive royalties on future net sales of the product. This collaboration provides potential treatment for patients suffering from centronuclear myopathy.

Competitive Analysis:

Global centronuclear myopathies drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Global centronuclear myopathies drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Current and future of global centronuclear myopathies drug market outlook in the developed and emerging marketsThe segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast periodRegions/Countries that are expected to witness the fastest growth rates during the forecast periodThe latest developments, market shares, and strategies that are employed by the major market players

Enquire for customization in Report @

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at

Editor Details

Last Updated: 23-Mar-2020